Impact of oral ibandronate 150mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT

Bone

Volumn 50, Issue 1, 2012, Pages 317-324

  Bock, Oliver ^a   Börst, Hendrikje ^a   Beller, Gisela ^a   Armbrecht, Gabriele ^a   Degner, Corina ^a   Martus, Peter ^a   Roth, Heinz Jürgen ^b   Felsenberg, Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Labor Limbach   (Germany)

Author keywords

3D pQCT; HR pQCT; Ibandronate; Microstructure; Osteoporosis

Indexed keywords

25 HYDROXYERGOCALCIFEROL; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE STRUCTURE; CALCIUM INTAKE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MICRO-COMPUTED TOMOGRAPHY; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RADIUS; RANDOMIZED CONTROLLED TRIAL; TIBIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; X-RAY MICROTOMOGRAPHY;

EID: 82355182617     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.027     Document Type: Article

References (27)

1. Boonen S., Singer A.J. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin 2008, 24:1781-1788.
2. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
3. Karpf D.B., Shapiro D.R., Seeman E., Ensrud K.E., Johnston C.C., Adami S., et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997, 277:1159-1164.
4. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
5. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
6. Burghardt A.J., Kazakia G.J., Sode M., de Papp A.E., Link T.M., Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in post-menopausal women with low bone density: relations between density, cortical and trabecular micro-architecture, biomechanics, and bone turnover. J Bone Miner Res 2010, 25:2282-2295.
7. Seeman E., Delmas P.D., Hanley D.A., Sellmeyer D., Cheung A.M., Shane E., et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
8. Rizzoli R., Laroche M., Krieg M.A., Frieling I., Thomas T., Delmas P., et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 2010, 30:1341-1348.
9. Chesnut I.C., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
10. Chesnut C.H., Ettinger M.P., Miller P.D., Baylink D.J., Emkey R., Harris S.T., et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005, 21:391-401.
11. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005, 20:1315-1322.
12. Stakkestad J.A., Lakatos P., Lorenc R., Sedarati F., Neate C., Reginster J.Y. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008, 27:955-960.
13. Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004, 15:792-798.
14. Lewiecki E.M., Keaveny T.M., Kopperdahl D.L., Genant H.K., Engelke K., Fuerst T., et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2009, 94:171-180.
15. Laib A., Rüegsegger P. Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. Bone 1999, 24:35-39.
16. Laib A., Häuselmann H.J., Rüegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care 1998, 6:329-337.
17. Laib A., Hildebrand T., Häuselmann H.J., Rüegsegger P. Ridge number density: a new parameter for in vivo bone structure analysis. Bone 1997, 21:541-546.
18. Laib A., Rüegsegger P. Comparison of structure extraction methods for in vivo trabecular bone measurements. Comput Med Imaging Graph 1999, 23:69-74.
19. Laib A., Newitt D.C., Lu Y., Majumdar S. New model-independent measures of trabecular bone structure applied to in vivo high-resolution MR images. Osteoporos Int 2002, 13:130-136.
20. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003, 73:423-432.
21. Pinheiro J.C., Bates D.M. Mixed-effects models in S and S-PLUS 2000, Springer, Berlin. 1st ed.
22. Seeman E., Chapurlat R., Cheung A., Felsenberg D., La-Roche M., Reeve J., et al. Risedronate reduces micro-structural deterioration of cortical bone accompanying menopause. Osteoporos Int 2010, 21:S9.
23. Recker R.R., Weinstein R.S., Chesnut C.H., Schimmer R.C., Mahoney P., Hughes C., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004, 15:231-237.
24. Baeksgaard L., Andersen K.P., Hyldstrup L. Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporos Int 1998, 8:255-260.
25. Brodt M.D., Ellis C.B., Silva M.J. Growing C57Bl/6 mice increase whole bone mechanical properties by increasing geometric and material properties. J Bone Miner Res 1999, 14:2159-2166.
26. Recker R.R. Architecture and vertebral fracture. Calcif Tissue Int 1993, 53(Suppl. 1):S139-S142.
27. Cohen A., Dempster D.W., Muller R., Guo X.E., Nickolas T.L., Liu X.S., et al. Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int 2010, 21:263-273.